title: DiaPep277 (DeveloGen).
abstract: DiaPep277, a 24-amino acid peptide based on residues 437 to 460 of heat shock protein 60, is undergoing phase II clinical trials by DeveloGen for the potential treatment and prevention of established and newly diagnosed type 1 diabetes symptoms of the prediabetic state and of latent autoimmune diabetes of the adult.
authors.affiliation: University of Pittsburgh School of Medicine, Diabetes Institute, Pittsburgh, PA 15213, USA. ngiann1@pitt.edu
authors.forename: Nick
authors.initials: N
authors.lastname: Giannoukakis
mesh_terms: D000818:Animals; D018834:Chaperonin 60; D017322:Clinical Trials, Phase II as Topic; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy*; D004345:Drug Industry; D006801:Humans; D007004:Hypoglycemic Agents / Q000737:chemistry / Q000627:therapeutic use*; D010446:Peptide Fragments; D010455:Peptides / Q000737:chemistry / Q000627:therapeutic use*; D013329:Structure-Activity Relationship; D016896:Treatment Outcome
chemical_list: D018834:Chaperonin 60; C447781:DiaPep 277; D007004:Hypoglycemic Agents; D010446:Peptide Fragments; D010455:Peptides